Literature DB >> 11336276

Substandard tuberculosis drugs on the global market and their simple detection.

K F Laserson1, A S Kenyon, T A Kenyon, T Layloff, N J Binkin.   

Abstract

SETTING: The prevalence of substandard anti-tuberculosis drugs is unknown. To maximize the effectiveness of tuberculosis (TB) control efforts, simple, inexpensive drug quality screening methods are needed.
DESIGN: Isoniazid (INH) and rifampin (RMP) single- and fixed-dose combination (FDC) formulations were collected from selected TB programs and pharmacies in Colombia, Estonia, India, Latvia, Russia and Vietnam. Samples were screened using a recently developed thin-layer chromatography (TLC) kit. All abnormal samples and a 40% random sample of normal formulations were further analyzed using confirmatory techniques. Samples outside of 85% to 115% of stated content, and/or containing compounds other than the stated drug, were defined as being substandard.
RESULTS: Overall, 10% (4/40) of all samples, including 13% (4/30) RMP samples, contained <85% of stated content. More FDCs (5/24, 21%) than single-drug samples (2/16, 13%) were substandard. A comparison of TLC with the confirmatory analysis for RMP analysis showed a sensitivity of 100% (4/4), a specificity of 92% (24/26), a positive predictive value (PPV) of 67% (4/6), and a negative predictive value (NPV) of 100% (24/24). An analysis of INH showed a specificity of 90% (9/10). However, sensitivity, PPV, and NVP could not be determined.
CONCLUSION: A substantial number of anti-tuberculosis drugs from several countries, in particular FDCs, were found to be substandard. Such drugs may contribute to the creation of drug-resistant TB. TLC is an effective, convenient, and inexpensive method for the detection of substandard drugs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11336276

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  19 in total

Review 1.  Substandard/counterfeit antimicrobial drugs.

Authors:  Theodoros Kelesidis; Matthew E Falagas
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

2.  Assessment of the quality of anti-tuberculosis medicines in Almaty, Kazakhstan, 2014.

Authors:  D Nabirova; G Schmid; R Yusupova; M Kantarbayeva; S I Ismailov; D Moffett; R W O Jähnke; J P Nuorti
Journal:  Int J Tuberc Lung Dis       Date:  2017-10-01       Impact factor: 2.373

Review 3.  Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.

Authors:  Roger K Verbeeck; Gunar Günther; Dan Kibuule; Christian Hunter; Tim W Rennie
Journal:  Eur J Clin Pharmacol       Date:  2016-06-15       Impact factor: 2.953

Review 4.  Multidrug resistance after inappropriate tuberculosis treatment: a meta-analysis.

Authors:  Marieke J van der Werf; Miranda W Langendam; Emma Huitric; Davide Manissero
Journal:  Eur Respir J       Date:  2011-10-17       Impact factor: 16.671

5.  Medicines informal market in Congo, Burundi and Angola: counterfeit and sub-standard antimalarials.

Authors:  Maria Cristina Gaudiano; Anna Di Maggio; Emilia Cocchieri; Eleonora Antoniella; Paola Bertocchi; Stefano Alimonti; Luisa Valvo
Journal:  Malar J       Date:  2007-02-22       Impact factor: 2.979

6.  A Repeat Random Survey of the Prevalence of Falsified and Substandard Antimalarials in the Lao PDR: A Change for the Better.

Authors:  Patricia Tabernero; Mayfong Mayxay; María Julia Culzoni; Prabha Dwivedi; Isabel Swamidoss; Elizabeth Louise Allan; Maniphone Khanthavong; Chindaphone Phonlavong; Chantala Vilayhong; Sengchanh Yeuchaixiong; Chanvilay Sichanh; Sivong Sengaloundeth; Harparkash Kaur; Facundo M Fernández; Michael D Green; Paul N Newton
Journal:  Am J Trop Med Hyg       Date:  2015-04-20       Impact factor: 2.345

7.  Drug-resistant tuberculosis in Mumbai, India: An agenda for operations research.

Authors:  Nerges Mistry; Monica Tolani; David Osrin
Journal:  Oper Res Health Care       Date:  2012-06

8.  Recent advances in tuberculosis and nontuberculous mycobacteria lung disease.

Authors:  Jae Seuk Park
Journal:  Tuberc Respir Dis (Seoul)       Date:  2013-06-25

9.  Combatting substandard and falsified medicines: a view from Rwanda.

Authors:  Agnes Binagwaho; Roger Bate; Michel Gasana; Corine Karema; Yves Mucyo; John Patrick Mwesigye; Floribert Biziyaremye; Cameron T Nutt; Claire M Wagner; Paul Jensen; Amir Attaran
Journal:  PLoS Med       Date:  2013-07-02       Impact factor: 11.069

Review 10.  Substandard drugs: a potential crisis for public health.

Authors:  Atholl Johnston; David W Holt
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.